Exclusive Summary

• Massive global patient base: Targeting over 60 million patients globally with schizophrenia and bipolar disorder, this crucial maintenance therapy guarantees stable, recurring cash flow for regional distributors.
• Formulation eliminates clinical pain points: Dispersible tablets can be easily dissolved in water or rapidly disperse in the mouth, perfectly addressing the severe non-compliance (e.g., pill cheeking/hiding) and dysphagia commonly seen in psychiatric patients.
• Prestigious clinical endorsements: Listed on the WHO Essential Medicines List (EML) and widely recommended as a first-line treatment by global guidelines, requiring minimal market education efforts.
• Robust supply chain and pricing elasticity: Benefiting from China's vertically integrated API-to-FDF manufacturing scale, the product offers aggressive pricing and substantial margin potential for overseas distribution partners without compromising quality.
• Regulatory-ready documentation: Availability of ready-to-file CTD dossiers facilitates rapid local regulatory submissions and shortens the time-to-market for international distributors.